Biologic-naive

Describes someone who has never had a biologic medicine before. Trials often report results separately for these people because first biologics tend to work better.

Also called: biologic naive, bio-naive, treatment-naive, treatment naive, anti-tnf naive

Related words biologic

Topics Research Biologics and newer medicines

Questions people ask

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

What is upadacitinib (Rinvoq) and how is it different from biologics?

Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.

Sources

Where to read more

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

The treatment-naive microbiome in new-onset Crohn's disease

Cell Host & Microbe Study Mar 2014 For professionals

A large study of the gut bacteria of children newly diagnosed with Crohn's, before any treatment. It found a clear pattern: more of certain potentially harmful bacteria and fewer of some helpful groups. Antibiotics made the imbalance worse. Samples from the rectum lining looked promising as a possible early diagnostic test.

Topics About Crohn's disease Research Children and young people

Jargon explained microbiome dysbiosis treatment-naive

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Jun 2026 Patients and professionals

An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.

Topics Biologics and newer medicines Research

Jargon explained network meta-analysis relative risk number needed to treat biosimilar

Biosimilar medicines

NHS England Web page Patients and professionals

NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.

Topics Biologics and newer medicines Medicines

Jargon explained biosimilar originator medicine switching

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Infliximab

Crohn's & Colitis UK Guide Jun 2024 For patients

A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.

Topics Biologics and newer medicines Monitoring

Jargon explained anti-TNF infusion subcutaneous biosimilar drug levels antibodies

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Search everything for "biologic-naive"